ViiV starts HIV prevention study

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has started a phase III study to evaluate long-acting injectable cabotegravir for the prevention of HIV infection.

The study will evaluate injections of cabotegravir given every two months compared to daily oral Pre-Exposure Prophylaxis (PrEP) with Truvada and is being conducted through a public-private collaboration of ViiV Healthcare, the HIV Prevention Trials Network (HPTN), the US National Institute of Allergy and Infectious Disease (NIAID) and Gilead Sciences.

At 2:30pm: (LON:GSK) GlaxoSmithKline PLC share price was +8.5p at 1541.5p

Story provided by